Table 2.
Prognostic factors evaluated by log-rank test survival analysis.
| Characteristics | Number | Median OS (months) | Log-rank test | Univariate |
|---|---|---|---|---|
| p value | p value | |||
| Sex | 0.625 | 0.765 | ||
| Male | 35 | 18 | ||
| Female | 27 | 17 | ||
| Age (years) | 0.752 | 0.654 | ||
| ≤ 50 | 30 | 20 | ||
| > 50 | 32 | 19 | ||
| Tumor location | 0.156 | 0.235 | ||
| Upper | 26 | 15 | ||
| Middle | 28 | 17 | ||
| Lower | 8 | 19 | ||
| Initial length | 0.023 | 0.164 | ||
| ≤ 5 cm | 35 | 21 | ||
| > 5 cm | 27 | 16 | ||
| Pathological grade | 0.102 | 0.274 | ||
| I | 12 | 20 | ||
| II | 39 | 18 | ||
| III | 11 | 15 | ||
| Initial clinical stage | 0.412 | 0.657 | ||
| II | 26 | 20 | ||
| III | 36 | 17 | ||
| Initial ECOG-PS | 0.758 | 0.458 | ||
| 0–1 | 39 | 19 | ||
| 2 | 23 | 18 | ||
| 3 | 0 | |||
| Initial radiation dose | 0.532 | 0.178 | ||
| ≥ 60 Gy | 57 | 19 | ||
| < 60 Gy | 5 | 18 | ||
| RFS | 0.001 | 0.001 | ||
| ≥ 12 month | 39 | 26 | ||
| < 12 month | 23 | 13.5 | ||
| Group | 0.352 | 0.473 | ||
| NBT+EBRT | 31 | 19 | ||
| EBRT | 31 | 18 |
EBRT external beam radiotherapy, ECOG-PS Eastern Cooperative Oncology Group performance status, NBT neutron intraluminal brachytherapy, RFS recurrence-free survival.